Rapid Screening in a Mouse Model of ALS
Author Information
Author(s): Richard J. Mead, Ellen J. Bennett, Aneurin J. Kennerley, Paul Sharp, Claire Sunyach, Paul Kasher, Jason Berwick, Brigitte Pettmann, Guiseppe Battaglia, Mimoun Azzouz, Andrew Grierson, Pamela J. Shaw
Primary Institution: Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom
Hypothesis
Can a new mouse model of ALS provide more consistent and rapid preclinical screening for therapies?
Conclusion
The new SOD1G93A mouse model shows consistent disease progression and allows for earlier detection of motor function decline, which can improve preclinical testing for ALS therapies.
Supporting Evidence
- The new mouse model shows a consistent disease course with reduced variability in motor function assessments.
- Early behavioral changes were detected before visible clinical signs, allowing for earlier intervention.
- Quantitative measures of motor function were developed to assess early disease progression.
Takeaway
Scientists created a special mouse to study ALS that helps them see problems with movement much earlier, making it easier to test new medicines.
Methodology
The study involved creating a new inbred mouse line and conducting six pharmacology studies to assess motor function and disease progression.
Potential Biases
Potential bias due to the genetic background of the mouse model and the subjective nature of some assessments.
Limitations
The study primarily focuses on a specific mouse model, which may not fully represent human ALS.
Participant Demographics
The study used C57BL/6 SOD1G93A transgenic mice and non-transgenic littermates.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website